Markets Soft as Earnings Season Grinds On
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
RBC's Yee Sees Interesting Buying Opportunities in Biotech Pullback (BIIB) (BMRN) (ESPR) (GILD)
May 4, 2015 10:21 AM EDTLast week was tough on biotech investors, with broad weakness in the space. The decline was similar to March's pullback, which was short-lived. In the view of analyst Michael J. Yee of RBC, investors are used to corrections, and the drop creates interesting buying opportunities.
Long ideas mentioned by Yee include Biogen (NASDAQ: BIIB), Vertex Pharma (NASDAQ: VRTX), BioMarin Pharma... More
